US 12,440,476 B2
Agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy
Karl A. Scheidt, Evanston, IL (US); Stephen J. Kron, Chicago, IL (US); and Yue Liu, Chicago, IL (US)
Assigned to Northwestern University, Evanston, IL (US); and The University of Chicago, Chicago, IL (US)
Filed by Northwestern University, Evanston, IL (US); and The University of Chicago, Chicago, IL (US)
Filed on Jul. 19, 2024, as Appl. No. 18/778,617.
Application 18/778,617 is a continuation of application No. PCT/US2023/060942, filed on Jan. 19, 2023.
Claims priority of provisional application 63/301,036, filed on Jan. 19, 2022.
Prior Publication US 2024/0374574 A1, Nov. 14, 2024
Int. Cl. A61K 31/4192 (2006.01); A61K 45/06 (2006.01); A61P 37/06 (2006.01)
CPC A61K 31/4192 (2013.01) [A61K 45/06 (2013.01); A61P 37/06 (2018.01)] 9 Claims
 
1. A method for inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising co-administering an inhibitor of telomerase reverse transcriptase (TERT) and a genotoxic therapy to the subject, wherein the subject has a disease or disorder associated with TERT activity and the subject is administered a non-therapeutic amount of the inhibitor of TERT to treat the disease or disorder associated with TERT activity.